MX2023007780A - Terapia de combinacion usando un anticuerpo anti-fucosil-gm1. - Google Patents

Terapia de combinacion usando un anticuerpo anti-fucosil-gm1.

Info

Publication number
MX2023007780A
MX2023007780A MX2023007780A MX2023007780A MX2023007780A MX 2023007780 A MX2023007780 A MX 2023007780A MX 2023007780 A MX2023007780 A MX 2023007780A MX 2023007780 A MX2023007780 A MX 2023007780A MX 2023007780 A MX2023007780 A MX 2023007780A
Authority
MX
Mexico
Prior art keywords
antibody
fucosyl
combination therapy
subject
lung cancer
Prior art date
Application number
MX2023007780A
Other languages
English (en)
Spanish (es)
Inventor
Yu Liu
Sarah Tannenbaum-Dvir
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2023007780A publication Critical patent/MX2023007780A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2023007780A 2021-01-08 2022-01-07 Terapia de combinacion usando un anticuerpo anti-fucosil-gm1. MX2023007780A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163135479P 2021-01-08 2021-01-08
PCT/US2022/011564 WO2022150557A1 (en) 2021-01-08 2022-01-07 Combination therapy using an anti-fucosyl-gm1 antibody

Publications (1)

Publication Number Publication Date
MX2023007780A true MX2023007780A (es) 2023-07-10

Family

ID=80119207

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023007780A MX2023007780A (es) 2021-01-08 2022-01-07 Terapia de combinacion usando un anticuerpo anti-fucosil-gm1.

Country Status (10)

Country Link
US (1) US20240050564A1 (https=)
EP (1) EP4274850A1 (https=)
JP (1) JP2024503379A (https=)
KR (1) KR20230129467A (https=)
CN (1) CN116745322A (https=)
AU (1) AU2022205648A1 (https=)
CA (1) CA3204392A1 (https=)
IL (1) IL304200A (https=)
MX (1) MX2023007780A (https=)
WO (1) WO2022150557A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201912657D0 (en) * 2019-09-03 2019-10-16 Scancell Ltd Binding members

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
US8383118B2 (en) 2005-12-08 2013-02-26 Medarex, Inc. Human monoclonal antibodies to fucosyl-GM1 and methods for using anti-fucosyl-GM1
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
JP6072771B2 (ja) 2011-04-20 2017-02-01 メディミューン，エルエルシー Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
HK1203971A1 (en) 2012-05-15 2015-11-06 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
US11104739B2 (en) * 2016-04-14 2021-08-31 Bristol-Myers Squibb Company Combination therapy using an anti-fucosyl-GM1 antibody and an anti-CD137 antibody
CN109475634A (zh) * 2016-06-03 2019-03-15 百时美施贵宝公司 用于治疗复发性小细胞肺癌的方法的抗-pd-1抗体
RU2765997C2 (ru) * 2017-03-30 2022-02-07 Мерк Патент Гмбх Комбинация анти-pd-l1 антитела и ингибитора днк-пк для лечения злокачественного новообразования
MY205645A (en) * 2018-06-23 2024-11-02 Genentech Inc Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor

Also Published As

Publication number Publication date
IL304200A (en) 2023-09-01
WO2022150557A1 (en) 2022-07-14
EP4274850A1 (en) 2023-11-15
JP2024503379A (ja) 2024-01-25
CA3204392A1 (en) 2022-07-14
KR20230129467A (ko) 2023-09-08
AU2022205648A9 (en) 2024-09-19
US20240050564A1 (en) 2024-02-15
CN116745322A (zh) 2023-09-12
AU2022205648A1 (en) 2023-08-24

Similar Documents

Publication Publication Date Title
MX2020008882A (es) Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
SA522433129B1 (ar) مركب بيريدازينيل-ثيازول كربوكساميد
PH12020551244A1 (en) Pd-1/pd-l1 inhibitors
BR112018070636A2 (pt) método de tratamento de um sujeito humano que tem câncer, anticorpo, uso de um anticorpo, anticorpo para uso, combinação de um anticorpo, kit para uso no tratamento de câncer, composição farmacêutica, anticorpo biespecífico, método para tratamento de câncer, anticorpo biespecífico para uso e método de depleção de células t reguladoras em um tumor sólido em um sujeito
MX2019008207A (es) Métodos para tratar el cáncer con anticuerpos anti-pd-1.
PH12018502409A1 (en) Use of glutamate modulating agents with immunotherapies to treat cancer
PH12021500004A1 (en) Pd-1/pd-l1 inhibitors
AU2017228470A8 (en) Combination therapy with anti-CD73 antibodies
MX2025001102A (es) Uso de virus oncoliticos, solos o en combinacion con un inhibidor de punto de control, para el tratamiento del cancer
PH12019502379A1 (en) Pd-1/pd-l1 inhibitors
PH12017501748A1 (en) Antibodies to icos
ZA201907135B (en) Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer
JOP20230118A1 (ar) مركب كربوكساميد أريل غير متجانس
MX393974B (es) Terapia de combinacion para tratamiento de cancer.
WO2016029073A3 (en) Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
EP3760229A3 (en) Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
PH12020551661A1 (en) Anti-pd-l1 antibody and use thereof
MX2024006765A (es) Terapia de combinación con adc ceacam5 - anti-pd1/pd-l1.
MX2019002728A (es) Combinacion de un anticuerpo anti-cd20, inhibidor de quinasa pi3-delta, y anticuerpo anti-pd-1 o anti-pd-l1 para el tratamiento hematologico de los canceres.
MX2021004226A (es) Terapia combinada contra el cáncer.
WO2022060986A3 (en) Methods of treating an individual that has failed an anti-pd-1/anti-pd-l1 therapy
MX2021010116A (es) Anticuerpo anti-pd-l1 y uso de este.
MX2024015058A (es) Terapia combinada de agente activo anti proteína de muerte programada 1 (pd-1), agente activo anti dominio 3 de inmunoglobulina y mucina de linfocitos t (tim-3) y agente activo anti gen 3 de activación de linfocitos (lag-3) para tratar el cáncer
MX2021000558A (es) Metodos para tratar el cancer de pulmon con un antagonista de fijacion al eje pd-1, un antimetabolito y un agente de platino.
MX2023003186A (es) Regimenes de dosificacion de anticuerpo anti-ilt4 o su combinacion con anticuerpo anti-pd-1 para el tratamiento de cancer.